Surrozen, Inc./DE (SRZN) Current Ratio
- Current ratio · latest quarter: Value 12.14×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 12.14× | Current assets / current liabilities. $109.40M ÷ $9.01M ≈ 12.14× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 109.40M USD | Assets, Current |
| Current obligations | 9.01M USD | Liabilities, Current |
| Cash and equivalents | 102.04M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 5.00M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.07M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $109.40M | $9.01M | $102.04M | (m) | $5.00M | (m) | $1.07M | (m) | 12.14× |
| 2026-03-31 | $113.95M | $9.56M | $106.91M | (m) | $5.00M | (m) | $889.00K | (m) | 11.91× |
| 2025-12-31 | $91.56M | $9.93M | $89.25M | (m) | $0.00 | (m) | $728.00K | (m) | 9.22× |
| 2025-09-30 | $85.86M | $6.53M | $81.33M | (m) | $2.32M | (m) | $538.00K | (m) | 13.15× |
| 2025-06-30 | $94.23M | $5.74M | $90.39M | (m) | $2.32M | (m) | $354.00K | (m) | 16.41× |
| 2025-03-31 | $106.01M | $10.58M | $101.64M | (m) | $2.13M | (m) | $302.00K | (m) | 10.02× |
| 2024-12-31 | $38.93M | $7.32M | $34.56M | (m) | $2.04M | (m) | $306.00K | (m) | 5.32× |
| 2024-09-30 | $45.29M | $6.12M | $31.01M | (m) | $12.20M | (m) | $276.00K | (m) | 7.40× |
| 2024-06-30 | $41.64M | $5.98M | $37.77M | (m) | $2.11M | (m) | $173.00K | (m) | 6.96× |
| 2024-03-31 | $32.02M | $6.18M | $27.29M | (m) | $2.13M | (m) | $131.00K | (m) | 5.18× |
| 2023-12-31 | $41.13M | $7.15M | $36.04M | (m) | $2.15M | (m) | $525.00K | (m) | 5.75× |
| 2023-09-30 | $48.36M | $6.67M | $33.98M | $9.46M | $1.98M | (m) | $287.00K | (m) | 7.25× |
| 2023-06-30 | $57.58M | $6.45M | $36.50M | $16.90M | $1.98M | (m) | $186.00K | (m) | 8.93× |
| 2023-03-31 | $67.03M | $7.79M | $27.81M | $33.94M | $1.98M | (m) | $171.00K | (m) | 8.61× |
| 2022-12-31 | $81.31M | $9.73M | $24.69M | $51.15M | $1.98M | (m) | $658.00K | (m) | 8.35× |
| 2022-09-30 | $82.72M | $8.65M | $25.53M | $52.86M | (m) | (m) | $362.00K | (m) | 9.56× |
| 2022-06-30 | $94.82M | $8.52M | $16.87M | $75.82M | (m) | (m) | $418.00K | (m) | 11.12× |
| 2022-03-31 | $95.68M | $8.12M | $14.30M | $78.21M | (m) | (m) | $1.04M | (m) | 11.79× |
| 2021-12-31 | $105.19M | $13.57M | $33.09M | $68.76M | $0.00 | (m) | $2.72M | (m) | 7.75× |
| 2021-09-30 | $114.00M | $12.54M | $61.10M | $49.07M | (m) | (m) | $1.83M | (m) | 9.09× |
| 2021-06-30 | $917.48K | $1.54M | $390.67K | (m) | (m) | (m) | (m) | (m) | 0.59× |
| 2021-03-31 | $1.41M | $986.59K | $774.93K | (m) | (m) | (m) | (m) | (m) | 1.43× |
| 2020-12-31 | $50.22M | $7.28M | $34.98M | $14.20M | (m) | (m) | $1.78M | (m) | 6.90× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |